Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme (LuxPARK)

August 5, 2025 updated by: Luxembourg Institute of Health

Biomaterial Collection for Neurodegenerative Disease Research (ND Collection)

The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

1800

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Luxembourg
      • Luxembourg, Luxembourg, 1210
        • Recruiting
        • Centre Hospitalier de Luxembourg (CHL), "Parkinson's Research Clinic"
        • Contact:
      • Luxembourg, Luxembourg, 1445
        • Recruiting
        • Clinical and Epidemiological Investigation Center (CIEC)
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Subjects with a neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism) and gender- and age-matched healthy controls.

Description

Inclusion Criteria:

  • Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism)
  • Subjects of all genders with a full capacity of consent
  • Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement
  • Subjects of at least 18 years of age at the time of inclusion

Exclusion Criteria:

  • Refusal to sign the informed consent
  • Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion
  • Active cancer
  • Pregnant women
  • Underage subjects of less than 18 years of age
  • Refusal to comply with mandatory sample collection
  • For invasive procedures, i.e., lumbar puncture and skin biopsy: relevant blood clotting impairment, e.g., anamnestic evidence of frequent or prolonged bleedings.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
PD patients
Subjects with neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism)
Other: Observational study with sample and data collection
Observational study with sample and data collection
Healthy controls
Gender- and age-matched healthy controls
Other: Observational study with sample and data collection
Observational study with sample and data collection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
1. Establish an open collection of a large set of diverse longitudinal bio-samples and data for research in 800 PD patients and 800 controls
Time Frame: through study completion, an average of 8 years
1.1. Samples will be aliquoted and stored according to the highest standards at the IBBL for future research.
through study completion, an average of 8 years
2. Stratification of parkinsonism into subtypes and definition of individual progression trajectories of PD.
Time Frame: through study completion, an average of 8 years
2.1. Identify PD patients' subgroups with a similar pattern of disease progression. datasets.
through study completion, an average of 8 years
Determine Parkinson's disease biomarker signatures
Time Frame: through study completion, an average of 8 years
3.1. Identify new and early diagnostic biomarkers
through study completion, an average of 8 years
Develop a mechanistic understanding of the disease
Time Frame: through study completion, an average of 8 years
4.1. Understand the mechanisms of PD pathogenesis.
through study completion, an average of 8 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Inform future studies testing new therapies for Parkinson's disease
Time Frame: through study completion, an average of 8 years
1.1. Enable future studies, such as clinical trials, by sharing the findings of mechanisms of PD pathogenesis and identifying new therapeutic targets.
through study completion, an average of 8 years
Harmonization of data with international Parkinson's disease cohort studies
Time Frame: through study completion, an average of 8 years
2.1. Data collected in this study will be harmonized with the international PD research community through an open-source digital platform.
through study completion, an average of 8 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Luxembourg Institute of Health

Collaborators

Centre Hospitalier du Luxembourg
University of Luxembourg
Laboratoire National de Santé (LNS)

Investigators

  • Principal Investigator: Rejko Rejko, Dr, Luxembourg Institute of Health

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 19, 2014

Primary Completion (Estimated)

December 31, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

June 17, 2021

First Submitted That Met QC Criteria

February 23, 2022

First Posted (Actual)

March 4, 2022

Study Record Updates

Last Update Posted (Actual)

August 6, 2025

Last Update Submitted That Met QC Criteria

August 5, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CNER 140174_ND

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on Observational study with sample and data collection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe